Skip to main content
. 2021 Oct 22;6(20):e138288. doi: 10.1172/jci.insight.138288

Figure 1. Maternal, fetal, and neonatal FABP4 circulating levels.

Figure 1

Serum samples were collected from 22 normoglycemic pregnant women and 18 women with GDM. All samples were collected at term, immediately before delivery. (A) FABP4 serum concentrations were determined using an ELISA assay and were correlated to BMI. (B) Comparison between FABP4 levels in normoglycemic pregnant woman (n = 22) and women with GDMA1 (n = 10) or GDMA2 (n = 8). (C) Serum samples, collected from umbilical artery (n = 22) and vein (n = 22) immediately after delivery of normoglycemic women were analyzed for FABP4 levels and compared with (normoglycemic) maternal (n = 22) concentrations. (D) Serum samples collected from neonates within the first few hours of life (n = 24) were analyzed for FABP4 levels and compared with fetal (n = 22) and maternal levels (n = 22). (E) FABP4 levels stratified to neonates who were small (SGA) (n = 7), appropriate (AGA) (n = 48), and large (LGA) (n = 5) for gestational age. (F) Birth weight of 40 neonates was correlated to FABP4 serum concentrations. Statistical analysis includes Spearman’s correlation test (A and F) and 1-way ANOVA (B–E). Data are shown as the mean ± SEM. *P < 0.05.